Pfizer Inc. (PFE) Short-Term Debt
The short-term debt for Pfizer Inc. (PFE) is $3.48 Billion with a year-over-year change of -49.84%. Short-term debt includes all borrowings and debt obligations due within one year, including the current portion of long-term debt, commercial paper, and credit facilities.
PFE Short-Term Debt Chart
Current Short-Term Debt
$3.48B
$3.48 Billion
Year-over-Year Change
-49.84%
vs. $6.95B prior year
Historical Data
30
Years of data available
Annual Short-Term Debt History
| Year | Short-Term Debt | YoY Change | % Change |
|---|---|---|---|
| 2025 | $3.48B | $-3.46B | -49.84% |
| 2024 | $6.95B | $-3.40B | -32.86% |
| 2023 | $10.35B | +$7.41B | +252.62% |
| 2022 | $2.93B | +$693.00M | +30.92% |
| 2021 | $2.24B | $-462.00M | -17.09% |
| 2020 | $2.70B | $-13.49B | -83.30% |
| 2019 | $16.19B | +$7.35B | +83.23% |
| 2018 | $8.84B | $-1.10B | -11.11% |
| 2017 | $9.94B | $-723.00M | -6.78% |
| 2016 | $10.66B | +$504.00M | +4.96% |
| 2015 | $10.16B | +$5.02B | +97.61% |
| 2014 | $5.14B | $-886.00M | -14.70% |
| 2013 | $6.03B | $-397.00M | -6.18% |
| 2012 | $6.42B | +$2.41B | +59.96% |
| 2011 | $4.02B | $-1.61B | -28.58% |
| 2010 | $5.62B | +$154.00M | +2.82% |
| 2009 | $5.47B | $-3.85B | -41.32% |
| 2008 | $9.32B | +$3.50B | +60.00% |
| 2007 | $5.83B | +$3.39B | +139.32% |
| 2006 | $2.43B | $-9.15B | -79.00% |
| 2005 | $11.59B | +$323.00M | +2.87% |
| 2004 | $11.27B | +$2.45B | +27.76% |
| 2003 | $8.82B | +$149.00M | +1.72% |
| 2002 | $8.67B | +$2.41B | +38.42% |
| 2001 | $6.26B | +$1.97B | +46.02% |
| 2000 | $4.29B | $-1.01B | -19.06% |
| 1999 | $5.30B | +$2.57B | +94.17% |
| 1998 | $2.73B | +$478.00M | +21.24% |
| 1997 | $2.25B | +$16.00M | +0.72% |
| 1996 | $2.23B | — | — |
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla